ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Eli Lilly
Eli Lilly
4 articles from Eli Lilly indexed by Voice Herald. Below is what Eli Lilly covers most and which stories they have contributed to.
Latest from Eli Lilly
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Eli Lilly
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Eli Lilly
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
Eli Lilly